Cellceutix Files Patent Application for its Cancer Compound
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Cellceutix Corporation has announced it has filed a U.S. patent application covering pharmaceutical formulations of a compound referred to as Kevetrin™ and many novel compounds having similar structures to Kevetrin. These structures cover a large number of compounds that Cellceutix can look at as possible drug development candidates.
The application covers the use of Kevetrin™ and the other compounds in various areas, including cancers. Cellceutix plans to file in other countries within a year of the U.S. filing.
George Evans, CEO stated: “This is a very exciting time for Cellceutix. The compounds covered by this patent application are structurally very different from anti-cancer agents currently on the market. Quite frankly, it took us longer than we expected to file this patent application due to the additional compounds that presented themselves as Kevetrin™ related structures. The result is a patent with new and expanded claims that will provide a strong intellectual property base for Kevetrin and a large portfolio of possible compounds for future development. In the meantime, we've been doing some very interesting experiments with Kevetrin and with our psoriasis candidate, KM-133. We anticipate announcing study results over the coming weeks."
The application covers the use of Kevetrin™ and the other compounds in various areas, including cancers. Cellceutix plans to file in other countries within a year of the U.S. filing.
George Evans, CEO stated: “This is a very exciting time for Cellceutix. The compounds covered by this patent application are structurally very different from anti-cancer agents currently on the market. Quite frankly, it took us longer than we expected to file this patent application due to the additional compounds that presented themselves as Kevetrin™ related structures. The result is a patent with new and expanded claims that will provide a strong intellectual property base for Kevetrin and a large portfolio of possible compounds for future development. In the meantime, we've been doing some very interesting experiments with Kevetrin and with our psoriasis candidate, KM-133. We anticipate announcing study results over the coming weeks."
